Detalles de la búsqueda
1.
Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.
J Infect Dis;
228(7): 907-918, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37498738
2.
Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.
Clin Infect Dis;
77(7): 1012-1020, 2023 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37338148
3.
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.
J Antimicrob Chemother;
78(9): 2323-2334, 2023 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37545164
4.
HIV-1 promoter is gradually silenced when integrated into BACH2 in Jurkat T-cells.
PeerJ;
8: e10321, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33282555
5.
Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector.
Sci Rep;
8(1): 10204, 2018 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29977044
Resultados
1 -
5
de 5
1
Próxima >
>>